Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04057352 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Citadel Embolization Device Study

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 26 to 25v19
  2. Study sites: 27 to 26v18
  3. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 28 to 27
    • Primary and study completion dates: Jun 30, 2026 to Nov 15, 2026
    v17
  4. Study sites: 27 to 28v16
  5. Study sites: 25 to 27v15
Show 13 earlier versionsHide 13 earlier versions
  1. Study sites: 24 to 25v14
  2. Study sites: 23 to 24v13
  3. Study sites: 21 to 23
    • Study completion date: Mar 30, 2027 to Jun 30, 2026
    • Start date: Jul 17, 2019 to Jul 18, 2019
    • Eligibility criteria expanded, about 22 words
    v12
  4. Primary completion date: Mar 30, 2026 to Jun 30, 2026
    • Study completion date: Jun 30, 2027 to Mar 30, 2027
    v11
  5. Primary endpoints revised (2)
    • Secondary endpoint revised
    v10
  6. Primary endpoints: 1 to 2v9 Show 4 more changesShow less
    • Trial status: Enrolling by Invitation to Recruiting
    • Study sites: 12 to 21
    • Eligibility criteria expanded, about 424 words
    • Secondary endpoint revised
  7. Primary completion date: Jun 17, 2024 to Mar 30, 2026
    • Study sites: 10 to 12
    • Study completion date: Dec 20, 2024 to Jun 30, 2027
    v8
  8. Enrollment target: 100 to 150v7 Show 5 more changesShow less
    • Primary completion date: Oct 17, 2023 to Jun 17, 2024
    • Study sites: 7 to 10
    • Study completion date: May 17, 2024 to Dec 20, 2024
    • Eligibility criteria expanded, about 1 word
    • Study description expanded, about 2 words
  9. Enrollment target: 30 to 100v6 Show 4 more changesShow less
    • Primary completion date: Oct 17, 2022 to Oct 17, 2023
    • Study completion date: May 17, 2023 to May 17, 2024
    • Study description shortened, about 1 word
    • Study title expanded, about 1 word
  10. Primary completion date: May 17, 2021 to Oct 17, 2022
    • Study sites: 3 to 7
    • Study completion date: May 17, 2022 to May 17, 2023
    v5
  11. Study sites: 1 to 3v4
  12. Primary completion date: Jul 17, 2020 to May 17, 2021
    • Study completion date: Jul 17, 2021 to May 17, 2022
    v3
  13. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to gather safety and effectiveness data on Stryker Neurovascular's Next Generation Target Detachable Coil (hereafter referred to as the Citadel Embolization Device), when used with Target Detachable Coils, in the treatment of wide-neck intracranial aneurysms.
Trial Details
NCT Number NCT04057352
Lead Sponsor Stryker Neurovascular
Conditions
(from sponsor)		 Unruptured Wide-neck Aneurysms
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov